Why MS Patients Should Know Their NAbs Status
Why MS Patients Should Know Their NAbs Status by Wendy
Mitchell
If you have multiple sclerosis (MS)--a chronic, progressive illness
affecting the nerves in the brain, spinal cord and central nervous
system--you're not alone. MS affects more than 400,000 people in
the United States, 2.5 million worldwide and two to three times as
many women as men.
The story of Sue Kelly, who was diagnosed with MS when she was
almost 40 years old, may inspire others.
Now 48, Sue has relapsing-remitting MS and her initial symptoms
included double vision. Following her diagnosis, she began taking
an interferon beta (IFN-ß) medication. "I considered myself
informed about MS. Then my physician told me that some patients
taking IFN-ß medication develop a form of antibody [proteins
of the immune system that develop in response to foreign
substances] to the medication."
These are called neutralizing antibodies, or NAbs, when they
interfere with--or neutralize--the activity of the IFN-ß.
Vision Problems
After Sue continued to experience vision problems, including seeing
halos, poor night vision and trouble seeing color, her physician
became concerned that her vision issues might be related to the
development of NAbs. He encouraged her to take a NAbs test.
Despite her occupation as a nurse and knowledge about MS, Sue
didn't realize that there might be a relationship between her NAbs
status and her treatment's effectiveness.
Her doctor explained that NAbs develop in 24 to 45 percent of all
MS patients treated with IFN-ß medications, and that in
individuals who maintain a high NAbs level over time, the clinical
efficacy of the medication seems to be reduced, as evidenced by
changes in magnetic resonance imaging (MRI) activity, relapse rates
and disease progression.
Double Vision Went Away
Sue was fortunate that her doctor insisted that she be tested, as
NAbs tests currently aren't part of standard MS clinical practice
for IFN-ß patients. After reviewing her lab results and
physical exam, her neurologist recommended that she switch
medications. Over the next six months, Sue's double vision
gradually went away.
"I feel relieved that I checked my NAbs status, and that I am doing
everything I can to manage my MS and protect my health," said
Sue.
For more information on NAbs, visit
http://main.nationalmssociety.org. To learn about new research
regarding NAbs, visit www.clinical trials.gov. If you have multiple
sclerosis, talk with your doctor about NAbs.
Article Directory: Article Dashboard
